H
Hangzhou Jiyuan Gene Technology
Committed to applying modern leading gene technology to develop innovative cellular immune products, focusing on the treatment of malignant tumors
About Hangzhou Jiyuan Gene Technology
Hangzhou Jiyuan Gene Technology Co., Ltd. (Celgenyx Bio) is a biopharmaceutical company established in 2020, founded by a group of senior American-educated scholars, entrepreneurs, and venture capitalists. The firm is strategically focused on the application of modern genetic technologies to develop and commercialize cell immunotherapy products specifically for the treatment of malignant tumors.
The company operates as a private, venture-capital-backed entity and has secured significant funding to advance its pipeline. A notable milestone was the completion of a 100 million yuan Series A financing round in 2022, led by the international investment firm Vivo Capital. This capital infusion supports the progression of its product candidates toward clinical application and industrialization. The company has established a comprehensive infrastructure in Hangzhou's Qiantang New District, which includes a research and development center, a GMP-compliant production workshop, and a quality control center, all of which became operational in 2021.
Celgenyx Bio's business model is centered on the research, development, and eventual sale of its proprietary cell therapy products. The company leverages a sophisticated technology suite that encompasses multiple platforms, including hybridoma antibody technology, antibody humanization, human antibody phage display, and CAR vector construction with lentiviral vector preparation. Furthermore, it has developed capabilities in human induced pluripotent stem cells (iPSC), covering their induction, identification, preparation, and gene editing. Through strategic partnerships and patent licensing, Celgenyx Bio has secured the rights to multiple global patents and in-licensed products for development and commercialization within the Greater China region, working closely with international research institutions and its U.S.-based affiliate, Celgenyx USA.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2022 | $14M | $55M | Vivo Capital | ↗ |
Growth signals
Latest recorded traffic for Hangzhou Jiyuan Gene Technology is 190 monthly website visits, down 9.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hangzhou Jiyuan Gene Technology in its local ecosystem
The Hangzhou Jiyuan Gene Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou Jiyuan Gene Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou Jiyuan Gene Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.

China's Jiyuan Bio raises ~$15M Series B for cell immunotherapy







